Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc. develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA). The Company is also developing ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The Company has two cell manufacturing facilities in Cambridge, Massachusetts and Copenhagen, Denmark. Vericel also operates a centralized cell manufacturing facility in Ann Arbor, Michigan.
